Mpox whitlow: a novel presentation.
Clinical and Experimental Dermatology 2023 March 23
BACKGROUND: Mpox is a rare zoonotic disease with a progressive increase in cases among men who have sex with men (MSM) worldwide in the last months. New complications of this infection have been described.
OBJECTIVES AND METHODS: To describe this new pattern of presentation of Mpox at the level of the finger.
RESULTS: We present 3 cases of Mpox whitlow, a new clinical presentation of Mpox. The patients were 3 MSM with ages ranging from 32 to 49 years. All three had involvement of the third finger of the dominant hand as well as skin lesions at other sites. Two of the three patients had severe inflammation in the digit and proximal arm and were treated with systemic corticosteroids with significant improvement. In 2 of the 3 cases we observed onychodystrophy as a complication. All patients reported sexual intercourse with previous digital anal penetration with the affected finger, which may be the mode of transmission.
CONCLUSIONS: We describe three cases of this Mpox clinical presentation with some distinguishing features that need to be considered.
OBJECTIVES AND METHODS: To describe this new pattern of presentation of Mpox at the level of the finger.
RESULTS: We present 3 cases of Mpox whitlow, a new clinical presentation of Mpox. The patients were 3 MSM with ages ranging from 32 to 49 years. All three had involvement of the third finger of the dominant hand as well as skin lesions at other sites. Two of the three patients had severe inflammation in the digit and proximal arm and were treated with systemic corticosteroids with significant improvement. In 2 of the 3 cases we observed onychodystrophy as a complication. All patients reported sexual intercourse with previous digital anal penetration with the affected finger, which may be the mode of transmission.
CONCLUSIONS: We describe three cases of this Mpox clinical presentation with some distinguishing features that need to be considered.
Full text links
Trending Papers
SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases.International Journal of Molecular Sciences 2023 May 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app